# RP3: Cedar henipavirus animal model

> **NIH NIH U19** · UNIVERSITY OF TEXAS MED BR GALVESTON · 2024 · $4,640,498

## Abstract

PROJECT SUMMARY/ABSTRACT – RP3 (Cedar Henipavirus Animal Model)
Henipaviruses are single-stranded, negative-sense enveloped RNA viruses of the paramyxovirus family.
Two henipaviruses, Nipah virus (NiV) and Hendra virus (HeV), cause a systemic and often fatal respiratory
and/or encephalitic disease in humans and ten other mammalian species. Importantly, NiV and HeV are
significant biothreats to humans and economically important livestock in Australia and Southeast Asia.
There are currently no vaccines or therapeutics approved for human use. Notably, development of
countermeasures for NiV and HeV is hampered by the fact that these viruses require BSL-4 containment,
meaning that very few research groups worldwide have access to the required biocontainment facilities to
perform preclinical studies with these important human viral pathogens. To address this problem, we are
developing a BSL-2 animal model that is based on Cedar virus (CedV), which is a non-pathogenic
henipavirus. Specifically, we are employing recombinant Cedar viruses (rCedVs) in which the NiV and HeV
fusion (F) and receptor-binding glycoprotein (G) are expressed in the rCedV genome, replacing CedV F and
G. Additionally, we have also incorporated our recently developed in vivo bioluminescence methodology to
longitudinally trace the dynamics and anatomical progression of rCedV-luciferase (rCedV-luc) infections in
individual animals. Using various approaches to inhibit the host innate immune response in mice, we have
demonstrated sustained replication of rCedV-luc and the rCedV-NiV-luc and rCedV-HeV-luc chimeras.
Importantly, whereas rCedV-luc does not establish stable expression in the brain, both of the chimeric
viruses do. Moreover, preliminary findings show that rCedV-NiV- luc causes neurological dysfunction and
death in specific strains of mice. The rCedV-luc platform is thus an authentic henipavirus system that can
be used to study henipavirus in vivo biology safely and expediently under BSL-2 containment. Our overall
hypothesis is that rCedV-luc infection of mice lacking specific innate immune responses represents a BSL-2
platform for the study of henipavirus biology and pathogenesis, as well as for development and testing of
anti-viral countermeasures. We will address this hypothesis through three Specific Aims: Aim 1: To optimize
the use of immunodeficient mice and rCedV-NiV-luc/rCedV-HeV-luc chimeras as a robust BSL2 model of
pathogenic henipavirus disease; Aim 2: To determine the mechanism of rCedV-NiV neurovirulence; Aim 3:
To define the efficacy and mechanisms of mAb-based therapeutics for CNS-resident henipavirus infections.
Aims involve synergistic collaborations with several other research projects and cores in this U19 program.
Successful completion of these Aims will establish the rCedV-luc mouse model as a robust BSL-2 platform
for the exploration of henipavirus pathogenesis and countermeasures.

## Key facts

- **NIH application ID:** 10862504
- **Project number:** 1U19AI181930-01
- **Recipient organization:** UNIVERSITY OF TEXAS MED BR GALVESTON
- **Principal Investigator:** Brian Schaefer
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $4,640,498
- **Award type:** 1
- **Project period:** 2024-07-30 → 2027-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10862504

## Citation

> US National Institutes of Health, RePORTER application 10862504, RP3: Cedar henipavirus animal model (1U19AI181930-01). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10862504. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*